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Background: Mutations in SCO2 cause cytochrome c oxidase deficiency (COX) and a fatal infantile
cardioencephalomyopathy. SCO2 encodes a protein involved in COX copper metabolism; supplementation with
copper salts rescues the defect in patients’ cells. Bezafibrate (BZF), an approved hypolipidemic agent, ameliorates
the COX deficiency in mice with mutations in COX10, another COX-assembly gene.
Methods: We have investigated the effect of BZF and copper in cells with SCO2 mutations using spectrophotometric
methods to analyse respiratory chain activities and a luciferase assay to measure ATP production..
Results: Individual mitochondrial enzymes displayed different responses to BZF. COX activity increased by about 40%
above basal levels (both in controls and patients), with SCO2 cells reaching 75-80% COX activity compared to
untreated controls. The increase in COX was paralleled by an increase in ATP production. The effect was dose-
dependent: it was negligible with 100 μM BZF, and peaked at 400 μM BZF. Higher BZF concentrations were
associated with a relative decline of COX activity, indicating that the therapeutic range of this drug is very narrow.
Combined treatment with 100 μM CuCl2 and 200 μM BZF (which are only marginally effective when administered
individually) achieved complete rescue of COX activity in SCO2 cells.
Conclusions: These data are crucial to design therapeutic trials for this otherwise fatal disorder. The additive effect of
copper and BZF will allow to employ lower doses of each drug and to reduce their potential toxic effects. The exact
mechanism of action of BZF remains to be determined.
Keywords: COX deficiency, Bezafibrate, SCO2, Copper chaperones, Copper supplementationBackground
Cytochrome c oxidase (COX), complex IV of the
mitochondrial respiratory chain (RC), is comprised of 13
structural subunits and a number of prosthetic groups and
metal cofactors [1]. For its biogenesis, COX requires
several ancillary proteins encoded by COX assembly
genes, which are needed for the synthesis of the prosthetic
groups, for the delivery of the metal cofactors, and for the
stabilization of the nascent polypeptides [2]. Mutations in* Correspondence: leonardo.salviati@unipd.it
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reproduction in any medium, provided the orCOX assembly genes (mainly SURF1, SCO2, and COX10)
are the most common cause of isolated COX deficiency
[3]. These disorders are characterized by severe encephalo-
myopathy, and involvement of other tissues (hypertrophic
cardiomyopathy in SCO2 patients[4], tubulopathy and/or
cardiomyopathy in COX10 patients[5]), and usually leads
to death in infancy or early childhood. There is no
established therapy for these conditions.
COX10 is required for heme biosynthesis [6], while the
precise function of SCO2 and SURF1 is still debated.
Homologues of SURF1 in bacteria appear to function as
heme-binding proteins [7], while SCO2 is implicated in
copper metabolism although its function is not completely
clear [4,8]. SCO2 itself is a copper-binding protein, and itLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Casarin et al. Orphanet Journal of Rare Diseases 2012, 7:21 Page 2 of 8
http://www.ojrd.com/content/7/1/21has been shown that copper supplementation can rescue
COX deficiency in cells harboring mutations in this gene
[9,10]. Although a preliminary trial in patients yielded
promising results [11], and supplementation with copper
salts is currently employed in patients with Menkes disease
[12], the potential toxicity of these compounds is a major
hindrance to their therapeutic use.
A novel approach for the treatment of RC disorders is
based on induction of mitochondrial biogenesis. This
was achieved in experimental models by overexpression
of PPARgamma -coactivator alpha (PGC-1alpha), or
by pharmacological treatment. Bezafibrate (BZF), an
approved hypolipidemic agent, was originally employed
in patients with disorders of mitochondrial fatty acid
metabolism with promising results [13]. It was later
shown to be effective also in RC disorders. Mice with
mitochondrial myopathy due to muscle-specific
knockout of the COX10 gene displayed increased muscle
COX activity and ATP levels, delayed onset of myopathy,
and markedly prolonged life span [14]. BZF proved
effective also in cells of patients with COX deficiency
[15]. Another approach is based on 5-aminoimidazole-4-
carboxamide ribonucleoside (AICAR). This compound
acts by activating AMP-activated protein kinase [16],
which in turn stimulates PGC-1alpha expression. AICAR
was found to be effective in mice with mutations in
SURF1, SCO2, and COX15 [17], whereas BZF was not
effective in mice and was associated with significant
toxicity in both control and COX-deficient animals.
However, the response to BZF is a species specific
phenomenon, and hepatomegaly after BZF treatment is
typical of rodents but is not usually seen in other
mammalian species, including humans[18,19]. Moreover,
AICAR is still not approved for human use, while BZF is
routinely employed in clinical practice. We therefore
examined the effect of BZF on a cellular model of SCO2
deficiency to see if this drug could have a role for the
treatment of patients with SCO2 mutations.
Materials and methods
Reagents and cell lines
Cell culture reagents were purchased from Invitrogen.
All other chemicals were purchased from Sigma.
Cell lines used in this work have been described previously
[10]. Briefly, Pt 1 and Pt 2 were compound heterozygotes for
the common SCO2 mutation E140K and for a truncating
mutation. Pt 3 was a compound heterozygote for two
truncating SURF1 mutations. Patients with coenzyme Q10
deficiency have been described previously [20].
Cell culture
Cell lines were cultured in Dulbecco modified Eagle
medium (DMEM) (Invitrogen) supplemented either with
20% fetal bovine serum (FBS) (primary skin fibroblasts)or with 10% FBS (all other cell lines), 100 mg/mL
streptomycin, and 100 units/mL penicillin.
Copper and BZF supplementation
BZF was solubilised in DMSO to obtain a 100 mM stock
solution. This stock solution was further diluted with
DMSO to the desired concentration. The total dose of
DMSO solvent in the culture medium was 0.5% for all
samples (i.e. 60 μL in 12 mL of medium). CuCl2 was
mixed in the medium before the addition of serum in
order to avoid precipitation. Cells were treated with BZF
alone for five days, whereas BZF+CuCl2 supplementa-
tion experiments were carried out for 10 days [10].
Biochemical assays
RC complexes were analyzed using standard spectro-
photometric assays as described[21,22]. Results were
normalized to total protein, and to citrate synthase (CS).
However, in copper supplementation experiments,
activities were normalized only to protein, because CS
activity is inhibited by high copper concentrations [10].
Ornithine aminotransferase (OAT) activity was measured
as described [23]. Statistical significance was calculated
as previously reported [10].
Immunoblot analysis
Equal amounts of total cell proteins were separated by
PAGE using 4-12% gradient gels and tris-glycine buffer
(Invitrogen). After blotting, membranes were probed
either with an antibody against COXII (Molecular
Probes) or with an antibody against SCO2 (Santa Cruz),
and with an anti actin antibody (Sigma) according to the
manufacturer’s protocol. Detection was performed using
the ECL advanced kit (GE biosciences). Densitometry
was performed using the ImageJ software.
Luminescence measurements
Luciferase assay was carried out, as previously described
[24]. In brief, wild type or SCO2 mutant fibroblasts
(200,000-300,000 per coverslip) were grown in the
presence or absence of 400 μM BZF for four days. They
were then transfected with mitochondrial targeted
luciferase (mtLUC) using the Amaxa Nucleofector appar-
atus (Lonza) and a standard electroporation procedure.
The cells were then treated for additional 24 h. The cover-
slips were transferred to the 37°C thermostated chamber
of a luminometer and perfused with a Krebs Ringer Buffer
containing: 125 mM NaCl, 5 mM KCl, 1 mM Na3PO4,
1 mM MgSO4, 20 μM Luciferin, 20 mM Hepes, 5,5 mM
Glucose (pH7,4). Luminescence is entirely dependent on
the continuously provided luciferin and proportional to
ATP concentration (between 20 and 200 μM). After 60 s
equilibration in the new medium, during which the light
emission of mitochondrial luciferase-transfected cells was
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than 10 cps, cellular response was evoked by adding the
agonist histamine (100 μM) to the perfusion medium.
Cell death and ROS measurements
4.5x104 cells grown in 12-well plates were treated with
BZF at the indicated concentration and after 4 days
treated with 1 mM H2O2 for 2 h . Cells were stained with
propidium iodide (PI) and annexin-V-FITC (Prodotti
Gianni) and cell death was measured by flow cytometry as
the percentage annexin-V, PI-positive cells[25]. ROS
production was assayed using dichlorodihydrofluorescein
diacetate and flow cytometry as described[26].
Results
BZF stimulates the activity of individual RC complexes
To study the effect of BZF treatment on the activity of
individual RC complexes, we incubated HeLa cells with
the reportedly effective dose of 400 μM BZF [14] for five
days. Cells were then harvested and RC enzyme activities
were measured on lysates. Activities of individual
enzymes were stimulated differently: the highest increase
was in the activity of complex I, while complex II was
unaffected, and the effect on complex III and IV activity
was intermediate (Figure 1A). We did not detect signifi-
cant variation also in the activities of citrate synthase
(CS) and of another mitochondrial matrix enzyme
unrelated to energetic metabolism, OAT (not shown).
BZF induces comparable increase of COX activity in
different cell lines
Next, we focused on the effect on COX in different cell
lines: HEK293 cells, primary skin fibroblasts from a
healthy individual, and bone marrow-derived SEM cells.
We detected similar increases of COX activity (+37%,
+38%, and +43%) in the three cell types compared toFigure 1 A) RC enzyme activities in HeLa Cells treated with 400 μM B
assayed for RC complex activities. * = significant difference versus untreated (p
line) were treated with 400 μM BZF as in panel A and then assayed for COX a
after BZF tretment.untreated samples (Figure 1B). In all cases, COX activity
was virtually 100% KCN-sensitive. Again we did not
detect significant variations of CS activity.
BZF stimulates COX activity in SCO2 cells in a dose-dependent
but peaks at 400 μM
We then analysed the effect of BZF in normal and COX-
deficient fibroblasts. Although this cell model is not ideal
because fibroblasts display only partial COX deficiency
(COX activity around 50% of controls), MyoD-transformed
fibroblasts, myoblasts or myotubes obtained from these
patients also displayed only partial COX deficiency [27]
and we detected the full COX-deficient phenotype only in
fully differentiated muscle. A similar phenomenon was
noted with other assembly factors such as FOXRED1 [28].
Therefore these cell types do not provide significant
advantages compared to skin fibroblasts for our studies.
To explore the dose-dependency of the treatment, we
incubated SCO2 mutant and control cells with increasing
doses of BZF (0, 100, 200, 400, 600 μM BZF) for five
days. With 100 μM BZF only a minimal response was
noted in both patient and controls (Figure 2), while there
was an increase of COX activity in both patient and
control, with a peak at 400 μM BZF, and a relative
decline at 600 μM BZF in both cell types (Figure 2). We
did not detect significant changes in CS activity even in
this case. In both cell types, the increase in COX activity
was paralleled by a similar increase in the steady state
levels of Cox2p (Figure 3A and 3B).
We considered whether the decline at higher BZF
concentrations could be caused by increased production
of reactive oxygen species (ROS), but we did not detect
significant variations of ROS in BZF treated cells (not
shown). This type of response to BZF was noted also in
HeLa cells (Figure 4A). In this case we analyzed also cell
death. Under basal conditions there was no increase ofZF. HeLa cells were incubated for 5 days with 400 μM BZF and then
<0.05). B) HEK293, primary skin fibrolasts and SEM cells (a leukaemia cell
ctivity. We did not detect significant changes in CS activity in any cell line
Figure 2 Primary skin fibroblasts of a normal control and of a
patients with SCO2 mutations were incubated with 0, 100, 200,
400, and 600 μM BZF for 5 days and then assayed for COX
activity. * = significant difference versus untreated (p<0.05).
** = significant versus 400 μM. Data are expressed normalized to
protein, but there was no variation when they were normalized to
CS activity.
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minor (albeit significant) increase in annexin-positive
cells after treatment with 600 μM BZF only after stimu-
lation with H2O2 (Figure 4B).
Because of the effect on COX activity observed in
these experiments, we treated with 400 μM BZF fibro-
blasts from two other patients, one with SCO2 mutations
and one with SURF1 mutations. We confirmed the effect
on the second SCO2 patient (+38%), whereas in the
SURF1 cells, although the relative increment of COXFigure 3 A) Lysates of cells treated with 400 μM BZF were
separated on a 4-12% gradient gel in a SDS-tris-glycine buffer.
After blotting, membranes were probed with anti COXII and anti-actin
antibodies. B) densitometric analysis of the previous gel (three different
experiments). Results are normalized to beta actin levels.activity was similar (+40%), the absolute increase was
much smaller (from 10% to 14% residual activity
compared to untreated controls) (Figure 5).
We confirmed the lack of stimulation of complex II in
cultured skin fibroblasts and we did not detect any
effect on CoQ10 content in CoQ10 deficient fibroblasts
(not shown).BZF increases ATP production in fibroblasts with SCO2
mutations
A mitochondrially targeted chimera of ATP-sensitive
photoprotein Luciferase (mtLUC) was exploited to dynam-
ically monitor ATP synthesis within the mitochondrial
subcellular compartment. The method is based on the
reaction of luciferase with the substrate luciferin in
presence of oxygen, as the resulting light emission is a
linear function of ATP concentration in a range between
10-3 and 10-2 M. SCO2 fibroblasts and normal controls
were grown for 5 days in the presence of 400 μM BZF
(see methods). ATP production was triggered by addition
of 100 μM histamine to the medium.
The increases [Ca2+] after stimulation with histamine in
the mitochondrial matrix cause an increase in ATP levels
due to the stimulation of Ca2+-dependent dehydrogenases.
This increment is impaired in cells with intrinsic
mitochondrial defects, such as the mitochondrial DNA
8344 A>G point mutation in the tRNALys gene [29]. In
accordance with these data we observed an increase of
ATP levels in mitochondria of normal cells (+19.1 ± 3%Figure 4 A) COX activity in HeLa cells treated with increasing
doses of BZF. B) Percentage of apoptotic cells under basal
conditions or after incubation with 1 mM H2O2 for 2 h.
Figure 5 COX activity in fibroblasts of a second SCO2 patient
and of a SURF1 patient were treated with 400 μM BZF for five
days. In SCO2 patient 2 the analysis could be performed only in
duplicate in BZF-treated cells. * = significant versus untreated
(p<0.05).
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(Figure 6A, Tr1), while this increment was absent in SCO2
cells (Figure 6B, Tr3).
We then evaluated the effect of BZF treatment. In
control cells, there was a reduction of the ATP increase
after stimulation with histamine (+10.5± 2% of the basal
levels) compared to untreated cells, (Figure 6A, Tr2), simi-
lar to what has been observed in cells overexpressing
PGC-1alpha, which display a reduction of Ca2+ transients
in the mitochondrial matrix [30] with reduced stimulation
of matrix dehydrogenases and a less evident rise in ATP
levels upon stimulation. In SCO2 mutant cells, we
observed the opposite effect, as BZF treatment caused a
significant increase in ATP levels (+10.4 ± 2% of basal
levels) after stimulation with histamine (Figure 6B, Tr3).
These data suggest that the biochemical defect was signifi-
cantly restored, with a detectable effect on the functional
output of mitochondria.Figure 6 Measurements of mitochondrial ATP concentration in contro
challenged with 100 μM histamine, black and grey traces refer to BZF treat
coverslips for each condition in 3 different experiments. Trace 1 (Tr1) = unt
patient; Tr4 = SCO2 patient + 400 μM BZF.BZF and CuCl2 display an additive effect in rescuing COX
deficiency in SCO2 cells
Copper was previously shown to rescue COX deficiency
in SCO2 mutant cells in a dose-dependent manner with
a maximum effect at 200 μM CuCl2, and the effect
required more than a week to become evident [10]. We
compared the effect of BZF and CuCl2, individually and
in combination. As seen in Figure 7, incubation with
suboptimal doses of either compound (100 μM CuCl2 or
200 μM BZF) caused only a minor increase of COX
activity, while incubation with the two compounds
together resulted in complete recovery of COX activity
in patient cells, similar to the effect of 200 μM CuCl2
alone (and much more evident than the effect of 400 μM
BZF alone). Moreover, longer incubation (10 versus
5 days) with BZF alone did not result in higher COX
activity compared to what we observed in previous
experiments.
Effect of CuCl2 or BZF treatment on SCO2 protein levels
Western blot analysis showed a marked reduction of
SCO2 protein consistent with the notion that the E140K
mutant is unstable [9,31] (Figure 8A and 8B). Treatment
with BZF did not significantly alter SCO2 levels in both
patient or control cells (Figure 8A), indicating that the
increase in COX activity observed is not mediated by
induction of SCO2 expression. We did not detect a
marked variation of SCO2 also after CuCl2 treatment
(Figure 8B). However densitometric analysis of three
different experiments did detect a small (but statistically
significant , p< 0.05) increase in the levels of SCO2 from
9± 5% of controls to 16 ± 7% of controls after treatment
with 200 μM CuCl2. These data must be taken with
caution because the SCO2 band in the patient is very
faint and densitometric analysis may be prone to errors,
nevertheless these finding could indicate that copper
supplementation may indeed function at least in part
through stabilization of the mutant protein. The modest
increase in SCO2 could explain the long incubation timel fibroblasts (A) and SCO2 cells (B). Where indicated the cells were
ed and untreated cells. The panel shows representative traces of 20
reated control; Tr2 = control + 400 μM BZF; Tr3 = untreated SCO2
Figure 7 Additive effect of copper and BZF. Cells were treated
with 200 μM BZF, 400 μM BZF, 100 μM CuCl2, 200 μM CuCl2, or with
200 μM BZF plus 100 μM CuCl2 for 10 days. * = significant versus
untreated (p<0.05). ** = significant versus untreated and versus cells
treated with 100 μM CuCl2 or 200 μM BZF (p<0.05).
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of COX deficiency in these cells [27].
Discussion
With the exception of coenzyme Q10 deficiency [32],
there is currently no established treatment for patients
with RC defects. Pharmacological stimulation of the
biogenesis of the RC is a promising new approach for
the treatment of these disorders. Two compounds have
been shown to be effective to this purpose. BZF, which
has been successfully employed in patients with defects
of mitochondrial beta-oxidation, was shown to be effect-
ive also in a mouse model of COX deficiency due toFigure 8 Western blot analysis of SCO2 in cells treated with 400
μM BZF (A) or 200 μM CuCl2 (B) for 10 days. Beta actin was used
as loading control.COX10 mutations [14], and in cells of patients with
COX deficiency due to COX10 mutation and with
unknown defects. However a recent study could not
confirm the efficacy of BZF in mice with defects in
SCO2, COX15, or SURF1, and it was found to cause
severe hepatomegaly in both control and COX-deficient
animals, whereas AICAR, another activator of the PPAR-
gamma/PGC-1alpha pathway, could rescue the phenotype
in these animals [17].
Yet, these negative results concerning the efficacy of
BZF should be taken with caution for two reasons. Mice
(and rodents in general) are not a good model to study
BZF. In fact it has been shown that there are marked
species-specific differences in the effects of BZF, which is
known to cause hepatomegaly in mice and rats, but not
in other mammals such as dogs and monkeys [18] (or
humans). The biological bases of this phenomenon are
not clear. In fact, BZF is commonly used in patients and
elevation of liver enzymes is an infrequent side effect in
clinical use [19]. Moreover, our results show that the
therapeutic window for BZF is very narrow (see below),
therefore dosage is a critical issue when administering
BZF to animals (or patients), and excessive doses may
result in lack of response. A possible explanation for the
observed lack of effectiveness of BZF in the COX
deficient mice models, could be that the plasma levels of
the drug fell outside the narrow therapeutic range
(animals were administered BZF in drinking water and
serum levels were not monitored). As pointed out by
Djouadi and Bastin mice received a dose of BZF 100-fold
the therapeutic dose used in patients[33].
Although the effects of AICAR in COX deficient mice
were striking, this compound is still not approved for
medical use, while BZF and copper are routinely used in
patients. We have therefore examined the effectiveness
of BZF (with or without copper) in human cells with
SCO2 deficiency, to assess the potential use of these
drugs in patients with SCO2 mutations. Our data
support the efficacy of the combined treatment with
these two compounds. Although in principle we cannot
rule out the hypothesis that the effect we observed
occurs only in cultured cells, and not in whole tissues,
nevertheless patients with beta oxidation defects receiv-
ing BZF therapy displayed an increase in COX activity in
their muscles [33]. Our results highlight some important
points that should be taken into account when designing
experiments in non rodent animal models, or therapeutic
trials in patients.
First, the response of COX activity to BZF treatment was
similar (an increase of about 40% compared to baseline
levels) in all cell lines we studied (primary fibroblasts, HeLa,
HEK293, and SEM cells), and the same relative increase
was also detected in COX-deficient cells (both in SCO2 and
SURF1 mutants), indicating that BZF does not increase
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COX biogenesis as a whole. The increase of COX activity
after BZF treatment was accompanied by increase of cellu-
lar ATP production in SCO2 cells.
However, the precise mechanism of action of BZF is
unclear[34]. In fact we detected an increase in enzymatic
activities of complex I, III, and IV, whereas other mito-
chondrial proteins, both matrix enzymes such as CS and
OAT, or localized to the mitochondrial inner membrane,
such as complex II and SCO2 protein itself, were
unaffected by BZF treatment, ruling out an effect of BZF
on mitochondrial biogenesis as a whole. Coenzyme Q10
levels in deficient cells were similarly unaffected. BZF
appears to be stimulating only RC complexes which
contain mitochondrial DNA encoded subunits, and not
mitochondrial biogenesis as a whole. These findings
argue against an involvement of the PGC1alpha pathway,
but the exact mechanism of action remains to be eluci-
dated. The apparently different mechanism of action of
AICAR and BZF suggest that these two compound could
also be used in synergy. Future work will be aimed to
test this hypothesis.
Second, we noted that the effect of BZF on COX activ-
ity peaks at a BZF concentration of 400 μM in the
culture medium. However, higher BZF concentrations
(600 μM) do not result in a plateau of the effect, but we
observed instead a relative reduction of COX activity. A
slight decrease of COX activity with 500 μM BZF was in
fact noted also by Bastin and coworkers [15] and they
did not test higher BZF doses. These results are critical
for therapeutic trials, because they imply that plasma
BZF levels must be closely monitored in patients, since
the therapeutic window for this compound appears to be
very narrow, and doses too high or too low will be
ineffective. The reason for the observed decrease in efficacy
at higher BZF concentrations is not clear. We observed a
minor increase in susceptibility to apoptosis in cells treated
with 600 μM BZF, but only after incubation with H2O2.
Some sort of negative feedback mechanism could be acting,
but further work is needed to address this issue.
Third, and most important, we demonstrated a syner-
gistic effect between copper and BZF. The effect of BZF
alone is relatively modest, but we had shown previously
that CuCl2 can rescue COX activity in SCO2 mutant
cells in a dose-dependent manner with complete recov-
ery of COX activity at 200 μM CuCl2 [10]. Preliminary
trials in patients have also yielded promising results,
although one major drawback is the toxicity of copper
[11]. Our present data demonstrate that CuCl2 and BZF
have an additive effect, which permits to employ lower
doses of each compound and still achieve complete
normalization of COX activity in patient’s cells. It will
be possible to avoid at least part of the toxicity relatedto high serum copper levels, while employing BZF at
doses lower than the peak effective levels of 400 μM.
Conclusions
Taken together, our data support the use of BZF in
combination with copper in patients with SCO2
mutations. We underscore the fact that both compounds
are routinely used in patients with other diseases there-
fore their utilization for SCO2 patients would simply
represent an off-label use. We also stress the importance
for clinicians, in particular pediatric neurologists
and cardiologists, to consider the possibility of SCO2
mutations in newborns and infants presenting with
hypertrophic cardiomyopathy of unexplained origin.
Early diagnosis is essential for the ultimate outcome of
patients because, as we learned from children with
CoQ10 deficiency [35], effective treatments may stop the
progression of the neurological disease but will not affect
the already established cerebral lesions.
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